Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Belzutifan: A Narrative Drug Review

Author(s): Vysakh Visweswaran and Keechilat Pavithran*

Volume 14, Issue 2, 2022

Published on: 23 May, 2022

Page: [88 - 95] Pages: 8

DOI: 10.2174/2589977514666220401094724

Price: $65

Abstract

Von Hippel-Lindau disease is an autosomal dominant disorder characterised by renal cell carcinomas, pancreatic neuroendocrine tumours, central nervous system hemangioblastomas, retinoblastomas, and tumours of the reproductive tract. This disease results from loss of function mutations in the tumour suppressor gene known as the Von Hippel-Lindau gene, located on chromosome 3. Loss of function mutation in the Von Hippel-Lindau gene results in the accumulation of a protein known as a hypoxia-inducible factor, which promotes cellular proliferation and angiogenesis, leading to cancer. Belzutifan inhibits the hypoxia-inducible factor by binding to the Per-ARNT -Sim-B binding pocket on the hypoxia-inducible factor -2α, inhibiting cellular proliferation and angiogenesis. In our thorough literature review, we identified 37 relevant articles. Belzutifan showed clinically meaningful response rates for both Von Hippel-Lindau disease-associated renal cell carcinomas and non-renal cell cancers. The pharmacokinetic profile of belzutifan was much better than its congener molecules due to the optimisation of its dihalide groups from germinal to vicinal. The pharmacodynamic effect of belzutifan was confirmed by its ability to decrease serum erythropoietin, which is a direct result of hypoxia-inducible factor- 2α inhibition. The significant side effects observed were anaemia, hypoxia, fatigue, hypertension, visual impairment and weight gain. Multiple clinical trials are currently underway to determine the role of beluztifan as part of combination regimens in treating Von Hippel-Lindau diseaseassociated malignancies.

Keywords: VHL, belzutifan, PT2977, MK-6482, HIF, RCC.

« Previous
Graphical Abstract

[1]
Clark PE, Cookson MS. The von Hippel-Lindau gene: Turning discovery into therapy. Cancer 2008; 113(7)(Suppl.): 1768-78.
[http://dx.doi.org/10.1002/cncr.23645] [PMID: 18800388]
[2]
Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A review of von hippel-lindau syndrome. J Kidney Cancer VHL 2017; 4(3): 20-9.
[http://dx.doi.org/10.15586/jkcvhl.2017.88] [PMID: 28785532]
[3]
Harlander S, Schönenberger D, Toussaint NC, et al. Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice. Nat Med 2017; 23(7): 869-77.
[http://dx.doi.org/10.1038/nm.4343] [PMID: 28553932]
[4]
Choueiri TK, Bauer TM, Papadopoulos KP, et al. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: A phase 1 trial and biomarker analysis. Nat Med 2021; 27(5): 802-5.
[http://dx.doi.org/10.1038/s41591-021-01324-7] [PMID: 33888901]
[5]
Yu Y, Yu Q, Zhang X. Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma. Drug Discov Today 2019; 24(12): 2332-40.
[http://dx.doi.org/10.1016/j.drudis.2019.09.008] [PMID: 31541711]
[6]
Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 2016; 539(7627): 112-7.
[http://dx.doi.org/10.1038/nature19796] [PMID: 27595394]
[7]
Arjumand W, Sultana S. Role of VHL gene mutation in human renal cell carcinoma. Tumour Biol 2012; 33(1): 9-16.
[http://dx.doi.org/10.1007/s13277-011-0257-3] [PMID: 22125026]
[8]
Shenoy N, Pagliaro L. Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: Putting it together with a transla-tional perspective. Ann Oncol 2016; 27(9): 1685-95.
[http://dx.doi.org/10.1093/annonc/mdw241] [PMID: 27329246]
[9]
U.S Food & Drug Administration. FDA approves belzutifan for cancers associated with von Hippel-Lindau disease. FDA Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease (Accessed on 2021 Oct 28).
[10]
Hasanov E, Jonasch E. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma. Expert Opin Investig Drugs 2021; 30(5): 495-504.
[http://dx.doi.org/10.1080/13543784.2021.1925248] [PMID: 33945366]
[11]
Fallah J, Rini BI. HIF inhibitors: Status of current clinical development. Curr Oncol Rep 2019; 21(1): 6.
[http://dx.doi.org/10.1007/s11912-019-0752-z] [PMID: 30671662]
[12]
Courtney KD, Infante JR, Lam ET, et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Oncol 2018; 36(9): 867-74.
[http://dx.doi.org/10.1200/JCO.2017.74.2627] [PMID: 29257710]
[13]
Srinivasan R, Donskov F, Iliopoulos O, et al. Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhib-itor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). J Clin Oncol 2021; 39(Suppl. 15): 4555.
[http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.4555]
[14]
Wiley H, Coleman HR, Jonasch E, et al. Oral HIF-2α inhibitor belzutifan for ocular von Hippel-Lindau (VHL) disease. Invest Ophthalmol Vis Sci 2021; 62: 32.
[15]
Papadopoulos KP, Jonasch E, Zojwalla NJ, Wang K, Bauer TM. A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors. J Clin Oncol 2018; 36(Suppl. 15): 2508.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.2508]
[16]
Choueiri TK, Plimack ER, Bauer TM, et al. Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). J Clin Oncol 2021; 38(Suppl. 6): 611.
[http://dx.doi.org/10.1200/JCO.2020.38.6_suppl.611]
[17]
Romero D. Belzutifan has potential in RCC. Nat Rev Clin Oncol 2021; 18(6): 322.
[http://dx.doi.org/10.1038/s41571-021-00517-w] [PMID: 33931768]
[18]
NIH. A food effect study in healthy volunteers with belzutifan (PT2977, MK-6482) tablets. Available from: https://clinicaltrials.gov/ct2/show/NCT03445169
[19]
Merck Sharp & Dohme Corp. WELIREG (belzutifan). NJ: Whitehouse station 2021.
[20]
Plimack ER, Hammers HJ, Choueiri TK, et al. A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2021; 39(Suppl. 15): TPS4594-.
[http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.TPS4594]
[21]
NIH. A trial of belzutifan (PT2977, MK-6482) in combination with cabozantinib in patients with Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003). Available from: https://clinicaltrials.gov/ct2/show/NCT03634540 (Accessed on 2021 Aug 30).
[22]
NIH. Belzutifan/MK-6482 for the treatment of advanced pheochromocytoma/ Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015). Available from: https://clinicaltrials.gov/ct2/show/NCT04924075 (Accessed on 2021 Aug 30).
[23]
NIH. Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482- 020). Available from: https://clinicaltrials.gov/ct2/show/NCT04995484 (Accessed on 2021 Aug 30).
[24]
NIH. A Study of Belzutifan (MK-6482) in participants with renal impairment (MK-6482-021). Available from: https://clinicaltrials.gov/ct2/show/NCT04994522 (Accessed on 2021 Aug 30).
[25]
NIH. A Study of Belzutifan (MK-6482) in participants with advanced clear cell renal cell carcinoma (MK-6482-018). Available from: https://clinicaltrials.gov/ct2/show/NCT04846920 (Accessed on 2021 Sept 4).
[26]
NIH. A Study of Belzutifan (MK-6482) in combination with lenvatinib versus cabozantinib for treatment of renal cell carcinoma (MK-6482-011). Available from: https://clinicaltrials.gov/ct2/show/NCT04586231 (Accessed on 2021 Sept 4).
[27]
NIH. A Study of Belzutifan (MK-6482) in participants with advanced renal cell carcinoma (MK-6482-013). Available from: https://clinicaltrials.gov/ct2/show/NCT04489771 (Accessed on 2021 Sept 4).
[28]
NIH. Pembrolizumab plus lenvatinib in combination with belzutifan in solid tumors (MK-6482-016). Available from: https://clinicaltrials.gov/ct2/show/NCT04976634 (Accessed on 2021 Sept 4).
[29]
NIH. A Study of pembrolizumab (mk-3475) in combination with belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/ Quavonlimab (MK-1308A) in combination with lenvatinib, versus pembrolizumab and lenvatinib, for treatment of advanced clear cell renal cell carcinoma (MK-6482-012). Available from: https://clinicaltrials.gov/ct2/show/NCT04736706 (Accessed on 2021 Sept 4).
[30]
NIH. A study of Belzutifan (MK-6482) versus everolimus in participants with advanced renal cell carcinoma (MK-6482-005). Available from: https://clinicaltrials.gov/ct2/show/NCT04195750 (Accessed on 2021 Sept 4).
[31]
Shen C, Kaelin WGJ Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013; 23(1): 18-25.
[http://dx.doi.org/10.1016/j.semcancer.2012.06.001] [PMID: 22705278]
[32]
Xu R, Wang K, Rizzi JP, et al. 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a hypoxia-inducible factor 2α (HIF-2α) inhibitor for the treatment of clear cell renal cell carcinoma. J Med Chem 2019; 62(15): 6876-93.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00719] [PMID: 31282155]
[33]
Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev 2013; 27(1): 41-53.
[http://dx.doi.org/10.1016/j.blre.2012.12.003] [PMID: 23291219]
[34]
Metelo AM, Noonan HR, Li X, et al. Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model. J Clin Invest 2015; 125(5): 1987-97.
[http://dx.doi.org/10.1172/JCI73665] [PMID: 25866969]
[35]
Burrows N, Maxwell PH. Hypoxia-inducible factor 2 inhibitors show promise in advanced kidney cancer. Nat Rev Urol 2021; 18(9): 516-7.
[http://dx.doi.org/10.1038/s41585-021-00487-9] [PMID: 34083800]
[36]
Garje R, An JJ, Sanchez K, et al. Current landscape and the potential role of hypoxia-inducible factors and selenium in clear cell renal cell carcinoma treatment. Int J Mol Sci 2018; 19(12): 3834.
[http://dx.doi.org/10.3390/ijms19123834] [PMID: 30513765]
[37]
Choueiri TK, Bauer TM, McDermott DF, et al. Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in com-bination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol 2021; 39(Suppl. 6): 272.
[http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.272]

Rights & Permissions Print Cite
Article Metrics
38
1
© 2024 Bentham Science Publishers | Privacy Policy